ArticleBreast cancer research : BCR2026
Contributing factors of contralateral breast cancer in patients with BRCA mutation (ON-BRCA II study, KoREa-BSG 11).
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cumulative risk of contralateral breast cancer (CBC) in BRCA1/2 carriers is remarkably higher than in non-carriers. This study aimed to investigate the clinicopathological predictors associated with the risk of metachronous CBC among breast cancer patients with BRCA1/2 mutations using correspondence analysis.
methodsThis retrospective study included patients who underwent BRCA testing between January 2008 and December 2018. The inclusion criterion was patients being between 20 and 80-years-old with invasive breast cancer (pT1-3, N0-3). We performed univariate and multivariate survival analyses to assess the risks associated with BRCA mutations, and conducted correspondence analysis to identify contributing factors for CBC among subgroup by age and BRCA mutations.
resultsTotal of 4009 patients were included in this analysis. After median follow-up of 93 months, 278 cases of CBC were documented. Among 576 patients with BRCA mutations, there was no difference in the incidence of CBC between BRCA1 and BRCA2 carriers (P = 0.07). Correspondence analysis revealed that, in younger patients (< 50 years) with BRCA1 mutations, the triple-negative subtype (r = 0.93) and high grade (r = 0.74) showed the closest geometric proximity associated with CBC. In BRCA2 carriers, high Ki-67 labeling index (≥ 20%) demonstrated prominent geometric association in the biplot related to CBC, regardless of age (r = 0.93).
conclusionAlthough no difference was found in the risk of CBC between BRCA 1/2 mutations, correspondence analysis revealed different contributing factors. For young BRCA carriers with a triple-negative subtype and poor pathologic parameters such as high grade and Ki-67 index, risk-reducing contralateral prophylactic mastectomy could be considered as a treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.